The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection
Open accessAbstract
IMPORTANCE: There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV). OBJECTIVE: To evaluate the rates of sustained virologic response (SVR) and adverse events in previously untreated patients with HCV genotype 1 and HIV co-infection following a 12-week treatment of the fixed-dose combination of ledipasvir and sofosbuvir. DESIGN, SETTING, AND PARTICIPANTS: Open-label, single-center, phase 2b pilot study of previously untreated, noncirrhotic patients with HCV genotype 1 and HIV co-infection conducted at the Clinical Research Center of the National Institutes of Health, Bethesda, Maryland, from June 2013 to September 2014. Patients included those receiving antiretroviral therapy with HIV RNA values of 50 copies/mL or fewer and a CD4 T-lymphocyte count of 100 cells/mL or greater or patients with untreated HIV infection with a CD4 T-lymphocyte count of 500 cells/mL or greater. Serial measurements of safety parameters, virologic and host immune correlates, and adherence were performed. INTERVENTIONS: Fifty patients with HCV genotype 1 never before treated for HCV were prescribed a fixed-dose combination of ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary study outcome was the proportion of patients with sustained viral response (plasma HCV RNA level <12 IU/mL) 12 weeks after end of treatment. RESULTS: Forty-nine of 50 participants (98% [95% CI, 89% to 100%]) achieved SVR 12 weeks after end of treatment, whereas 1 patient experienced relapse at week 4 following treatment. In the patient with relapse, deep sequencing revealed a resistance associated mutation in the NS5A region conferring resistance to NS5A inhibitors, such as ledipasvir. The most common adverse events were nasal congestion (16% of patients) and myalgia (14%). There were no discontinuations or serious adverse events attributable to study drug. CONCLUSIONS AND RELEVANCE: In this open-label, uncontrolled, pilot study enrolling patients co-infected with HCV genotype 1 and HIV, administration of an oral combination of ledipasvir and sofosbuvir for 12 weeks was associated with high rates of SVR after treatment completion. Larger studies that also include patients with cirrhosis and lower CD4 T-cell counts are required to understand if the results of this study generalize to all patients co-infected with HCV and HIV. TRIAL REGISTRATION: clinicaltrials.gov Identifier:NCT01878799.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Cited by
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
Panel, A.-I. H. G., Chung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E., Aronsohn, A. I., Bhattacharya, D., Broder, T., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy585 · Cited by 717
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., Marks, K., Luetkemeyer, A., Baden, R. P., Sax, P. E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501315 · Cited by 470
Self-citationDaclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Wyles, D. L., Ruane, P. J., Sulkowski, M. S., Dieterich, D., Luetkemeyer, A., Morgan, T. R., Sherman, K. E., Dretler, R., Fishbein, D., Gathe, J. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503153 · Cited by 419
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study
Silverberg, M. J., Lau, B., Achenbach, C. J., Jing, Y., Althoff, K. N., D'Souza, G., Engels, E. A., Hessol, N. A., Brooks, J. T., Burchell, A. N., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2768 · Cited by 328
Metadata
- Authors
- Osinusi, A., Townsend, K., Kohli, A., Nelson, A., Seamon, C., Meissner, E. G., Bon, D., Silk, R., Gross, C., Price, A., Sajadi, M., Sidharthan, S., Sims, Z., Herrmann, E., Hogan, J., Teferi, G., Talwani, R., Proschan, M., Jenkins, V., Kleiner, D. E., Wood, B. J., Subramanian, G. M., Pang, P. S., McHutchison, J. G., Polis, M. A., Fauci, A. S., Masur, H., & Kottilil, S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-03-24
- Volume
- 313
- Issue
- 12
- Pages
- 1232
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2030470608
- Cited by
- 203
- References
- 1
- FWCI
- 26.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. https://app.cochat.ai/papers/10.1001/jama.2015.1373
- The paper
- Osinusi, A., Townsend, K., Kohli, A., Nelson, A., Seamon, C., Meissner, E. G., Bon, D., Silk, R., Gross, C., Price, A., Sajadi, M., Sidharthan, S., Sims, Z., Herrmann, E., Hogan, J., Teferi, G., Talwani, R., Proschan, M., Jenkins, V., . . . Kottilil, S. (2015). Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. JAMA. https://doi.org/10.1001/jama.2015.1373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.